» Articles » PMID: 38356008

Methyl-C-L-methionine Positron Emission Tomography for Radiotherapy Planning for Recurrent Malignant Glioma

Overview
Journal Ann Nucl Med
Date 2024 Feb 15
PMID 38356008
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate differences in uptake regions between methyl-C-L-methionine positron emission tomography (C-MET PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI), and their impact on dose distribution, including changing of the threshold for tumor boundaries.

Methods: Twenty consecutive patients with grade 3 or 4 glioma who had recurrence after postoperative radiotherapy (RT) between April 2016 and October 2017 were examined. The study was performed using simulation with the assumption that all patients received RT. The clinical target volume (CTV) was contoured using the Gd-enhanced region (CTV(Gd)), the tumor/normal tissue (T/N) ratios of C-MET PET of 1.3 and 2.0 (CTV (T/N 1.3), CTV (T/N 2.0)), and the PET-edge method (CTV(P-E)) for stereotactic RT planning. Differences among CTVs were evaluated. The brain dose at each CTV and the dose at each CTV defined by C-MET PET using MRI as the reference were evaluated.

Results: The Jaccard index (JI) for concordance of CTV (Gd) with CTVs using C-MET PET was highest for CTV (T/N 2.0), with a value of 0.7. In a comparison of pixel values of MRI and PET, the correlation coefficient for cases with higher JI was significantly greater than that for lower JI cases (0.37 vs. 0.20, P = 0.007). D50% of the brain in RT planning using each CTV differed significantly (P = 0.03) and that using CTV (T/N 1.3) were higher than with use of CTV (Gd). V90% and V95% for each CTV differed in a simulation study for actual treatment using CTV (Gd) (P = 1.0 × 10 and 3.0 × 10, respectively) and those using CTV (T/N 1.3) and CTV (P-E) were lower than with CTV (Gd).

Conclusions: The region of C-MET accumulation is not necessarily consistent with and larger than the Gd-enhanced region. A change of the tumor boundary using C-MET PET can cause significant changes in doses to the brain and the CTV.

References
1.
Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View

2.
Mineura K, Sasajima T, Suda Y, Kowada M, Shishido F, Uemura K . Amino acid study of cerebral gliomas using positron emission tomography--analysis of (11C-methyl)-L-methionine uptake index. Neurol Med Chir (Tokyo). 1990; 30(13):997-1002. DOI: 10.2176/nmc.30.997. View

3.
Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9):1199-208. PMC: 4999003. DOI: 10.1093/neuonc/now058. View

4.
Ullrich R, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H . Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009; 50(12):1962-8. DOI: 10.2967/jnumed.109.065904. View

5.
Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View